D3 Bio Inc., a global clinical-stage biotechnology company dedicated to developing innovative oncology therapeutics, announced first-line (1L) clinical data of elisrasib monotherapy and elisrasib in ...
Morning Overview on MSN
A new tool called PerturbFate can now predict how thousands of genetic mutations drive disease at once — aimed squarely at cancer and Alzheimer’s
A melanoma cell can dodge a targeted drug in dozens of different ways, each driven by a different genetic mutation. But what ...
Morning Overview on MSN
PerturbFate, a new AI, can now forecast how tens of thousands of mutations push cells toward cancer at once — pointing drug makers straight at the ones that matter
Melanoma kills roughly 8,000 Americans each year, and a stubborn share of those deaths trace back to the same problem: tumors ...
The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...
Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge. Mutations in DNA damage response (DDR) pathway ...
WUHAN, HUBEI PROVINCE, CHINA, February 15, 2026 /EINPresswire.com/ — In the complex landscape of life science research, selecting the right cellular model is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results